Publication

Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis

Vierboom, M. P. M., Breedveld, E., Kap, Y. S., Mary, C., Poirier, N., 't Hart, B. A. & Vanhove, B., Mar-2016, In : Clinical and Experimental Immunology. 183, 3, p. 405-418 14 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Vierboom, M. P. M., Breedveld, E., Kap, Y. S., Mary, C., Poirier, N., 't Hart, B. A., & Vanhove, B. (2016). Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis. Clinical and Experimental Immunology, 183(3), 405-418. https://doi.org/10.1111/cei.12739

Author

Vierboom, M. P. M. ; Breedveld, E. ; Kap, Y. S. ; Mary, C. ; Poirier, N. ; 't Hart, B. A. ; Vanhove, B. / Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis. In: Clinical and Experimental Immunology. 2016 ; Vol. 183, No. 3. pp. 405-418.

Harvard

Vierboom, MPM, Breedveld, E, Kap, YS, Mary, C, Poirier, N, 't Hart, BA & Vanhove, B 2016, 'Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis', Clinical and Experimental Immunology, vol. 183, no. 3, pp. 405-418. https://doi.org/10.1111/cei.12739

Standard

Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis. / Vierboom, M. P. M.; Breedveld, E.; Kap, Y. S.; Mary, C.; Poirier, N.; 't Hart, B. A.; Vanhove, B.

In: Clinical and Experimental Immunology, Vol. 183, No. 3, 03.2016, p. 405-418.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Vierboom MPM, Breedveld E, Kap YS, Mary C, Poirier N, 't Hart BA et al. Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis. Clinical and Experimental Immunology. 2016 Mar;183(3):405-418. https://doi.org/10.1111/cei.12739


BibTeX

@article{60ba3e7a9baf4ace80b5e8bd4d26f8ca,
title = "Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis",
abstract = "T cells have a central pathogenic role in the aetiopathogenesis of rheumatoid arthritis (RA), and are therefore a favoured target of immunotherapy aiming at physical or functional elimination. Here we report an efficacy test of FR104, a new co-stimulation inhibitor directly targeting CD28 on T cells, in a translationally relevant model, the rhesus monkey model of collagen-induced arthritis (CIA). As a relevant comparator we used abatacept [cytotoxic T lymphocyte antigen immunoglobulin (CTLA Ig)], an antagonist of CTLA-4 binding to CD80/86 clinically approved for treatment of RA. Treatment with either compound was started at the day of CIA induction. Although FR104 previously demonstrated a higher control of T cell responses in vitro than abatacept, both compounds were equally potent in the suppression of CIA symptoms and biomarkers, such as the production of C-reactive protein (CRP) and interleukin (IL)-6 and anti-collagen type II (CII) serum antibody (IgM/IgG). However, in contrast to abatacept, FR104 showed effective suppression of CII-induced peripheral blood mononuclear cell (PBMC) proliferation. The current study demonstrates a strong potential of the new selective CD28 antagonist FR104 for treatment of RA.",
keywords = "CD28, CIA, co-stimulation blockade, rhesus monkey, T cell, EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS, ACTIVE RHEUMATOID-ARTHRITIS, CLASS-I REGION, RHESUS-MONKEYS, RENAL-ALLOGRAFT, DOUBLE-BLIND, ANTIBODIES, CTLA4IG, COSTIMULATION, ACTIVATION",
author = "Vierboom, {M. P. M.} and E. Breedveld and Kap, {Y. S.} and C. Mary and N. Poirier and {'t Hart}, {B. A.} and B. Vanhove",
year = "2016",
month = "3",
doi = "10.1111/cei.12739",
language = "English",
volume = "183",
pages = "405--418",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley",
number = "3",

}

RIS

TY - JOUR

T1 - Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis

AU - Vierboom, M. P. M.

AU - Breedveld, E.

AU - Kap, Y. S.

AU - Mary, C.

AU - Poirier, N.

AU - 't Hart, B. A.

AU - Vanhove, B.

PY - 2016/3

Y1 - 2016/3

N2 - T cells have a central pathogenic role in the aetiopathogenesis of rheumatoid arthritis (RA), and are therefore a favoured target of immunotherapy aiming at physical or functional elimination. Here we report an efficacy test of FR104, a new co-stimulation inhibitor directly targeting CD28 on T cells, in a translationally relevant model, the rhesus monkey model of collagen-induced arthritis (CIA). As a relevant comparator we used abatacept [cytotoxic T lymphocyte antigen immunoglobulin (CTLA Ig)], an antagonist of CTLA-4 binding to CD80/86 clinically approved for treatment of RA. Treatment with either compound was started at the day of CIA induction. Although FR104 previously demonstrated a higher control of T cell responses in vitro than abatacept, both compounds were equally potent in the suppression of CIA symptoms and biomarkers, such as the production of C-reactive protein (CRP) and interleukin (IL)-6 and anti-collagen type II (CII) serum antibody (IgM/IgG). However, in contrast to abatacept, FR104 showed effective suppression of CII-induced peripheral blood mononuclear cell (PBMC) proliferation. The current study demonstrates a strong potential of the new selective CD28 antagonist FR104 for treatment of RA.

AB - T cells have a central pathogenic role in the aetiopathogenesis of rheumatoid arthritis (RA), and are therefore a favoured target of immunotherapy aiming at physical or functional elimination. Here we report an efficacy test of FR104, a new co-stimulation inhibitor directly targeting CD28 on T cells, in a translationally relevant model, the rhesus monkey model of collagen-induced arthritis (CIA). As a relevant comparator we used abatacept [cytotoxic T lymphocyte antigen immunoglobulin (CTLA Ig)], an antagonist of CTLA-4 binding to CD80/86 clinically approved for treatment of RA. Treatment with either compound was started at the day of CIA induction. Although FR104 previously demonstrated a higher control of T cell responses in vitro than abatacept, both compounds were equally potent in the suppression of CIA symptoms and biomarkers, such as the production of C-reactive protein (CRP) and interleukin (IL)-6 and anti-collagen type II (CII) serum antibody (IgM/IgG). However, in contrast to abatacept, FR104 showed effective suppression of CII-induced peripheral blood mononuclear cell (PBMC) proliferation. The current study demonstrates a strong potential of the new selective CD28 antagonist FR104 for treatment of RA.

KW - CD28

KW - CIA

KW - co-stimulation blockade

KW - rhesus monkey

KW - T cell

KW - EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS

KW - ACTIVE RHEUMATOID-ARTHRITIS

KW - CLASS-I REGION

KW - RHESUS-MONKEYS

KW - RENAL-ALLOGRAFT

KW - DOUBLE-BLIND

KW - ANTIBODIES

KW - CTLA4IG

KW - COSTIMULATION

KW - ACTIVATION

U2 - 10.1111/cei.12739

DO - 10.1111/cei.12739

M3 - Article

VL - 183

SP - 405

EP - 418

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 3

ER -

ID: 41414659